Intestinal-type and pancreatobiliary-type adenocarcinomas: How does ampullary carcinoma differ from other periampullary malignancies?

Annals of Surgical Oncology

Volumn 20, Issue 2, 2013, Pages 430-439

  Westgaard, Arne ^a,b   Pomianowska, Ewa ^a,b   Clausen, Ole Petter F ^a,b   Gladhaug, Ivar P ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; AGED; AMPULLARY ADENOCARCINOMA; ARTICLE; BILE DUCT ADENOCARCINOMA; BILE DUCT CARCINOMA; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DUODENUM ADENOCARCINOMA; DUODENUM CARCINOMA; FEMALE; GASTROINTESTINAL CARCINOMA; HISTOPATHOLOGY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PANCREATOBILIARY ADENOCARCINOMA;

AGED; AMPULLA OF VATER; CELL DIFFERENTIATION; COMMON BILE DUCT NEOPLASMS; DUODENAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; SURVIVAL RATE;

EID: 84878842902     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2603-0     Document Type: Article

References (36)

1. Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am. 2001;81:543-55.
2. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764-72.
3. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 2009;100:598-605.
4. Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379-87.
5. Albores-Saavedra J, Henson DE, Klimstra DS. Malignant epithelial tumors of the ampulla. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, DC: Armed Forces Institute of Pathology; 2000. p. 259-316.
6. Albores-Saavedra J, Hruban RH, Klimstra DS, Zamboni G. Invasive adenocarcinoma of the ampullary region. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. p. 87-91.
7. Heinrich S, Clavien PA. Ampullary cancer. Curr Opin Gastroenterol. 2010;26:280-5.
8. Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8:170.
9. Schirmacher P, Buchler MW. Ampullary adenocarcinoma - differentiation matters. BMC Cancer. 2008;8:251.
10. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Tumors of the ampulla of Vater: histopathologic classification and predictors of survival. J Am Coll Surg. 2008;207:210-8.
11. Bosnan FT. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
12. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036-49.
13. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385-7.
14. Westgaard A, Laronningen S, Mellem C, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer. 2009;45:2850-9.
15. Westgaard A, Clausen OPF, Gladhaug IP. Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports. APMIS. 2011;119:689-700.
16. Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OPF, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54:337-47.
17. Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J Surg Oncol. 2012;105:266-72.
18. Romiti A, Barucca V, Zullo A, et al. Tumors of ampulla of Vater: a case series and review of chemotherapy options. World J Gastrointest Oncol. 2012;4:60-7.
19. Amptoulach S, Josefsson A, Kavantzas N, Kalaitzakis E. Adenocarcinoma of the ampulla of Vater: does the histopathologic type matter? Scand J Gastroenterol. 2011;46:1401-3.
20. Kimura W, Futakawa N, Yamagata S, et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994;85:161-6.
21. Ampulla of Vater. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. AJCC cancer staging manual. 7th edition. Chicago: Springer; 2010. p. 235-40.
22. Frierson HF Jr. The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla. Am J Surg Pathol. 1989;13:146-62.
23. Verbeke CS. Resection margins and R1 rates in pancreatic cancer - are we there yet? Histopathology. 2008;52:787-96.
24. Kohler I, Jacob D, Budzies J, et al. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011;135:202-11.
25. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol. 2007;11:3-9.
26. Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer. 2003;2:13.
27. Albores-Saavedra J, Henson DE, Klimstra DS. Dysplasia, carcinoma in situ, and invasive carcinoma of the extrahepatic bile ducts. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C.: Armed Forces Institute of Pathology; 2000. p. 191-215.
28. de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256-63.
29. Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607-13.
30. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 1.2012. http://www.nccn.org/ professionals/physician-gls/pdf/pancreatic.pdf.
31. Furuse J, Takada T, Miyazaki M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:55-62.
32. Struck A, Howard T, Chiorean EG, Clarke JM, Riffenburgh R, Cardenes HR. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol. 2009;100:144-8.
33. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514-9.
34. Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.
35. Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011;37:791-7.
36. Neoptolemos JP, Moore MJ, Cox TF, et al. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29(Suppl):LBA4006.